Navigation Links
Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease
Date:7/17/2008

- Dimebon Improved the Clinical Course of Alzheimer's Disease; Patients Experienced Statistically Significant Improvements in Memory and Thinking,

Activities of Daily Living, Behavior and Overall Function -

SAN FRANCISCO, July 17 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced publication of the results of its first Alzheimer's disease pivotal clinical trial of the investigational drug Dimebon in the July 19, 2008 issue of The Lancet. In this double-blind, placebo-controlled trial, patients with mild-to-moderate Alzheimer's disease treated with Dimebon experienced statistically significant improvements compared to placebo in all the key aspects of the disease: memory and thinking, activities of daily living, behavior and overall function.

After both six months and a full year of treatment, Dimebon-treated patients were significantly better than placebo-treated patients on all key aspects of the disease. The benefit on the primary endpoint, the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) at six months, was highly significant (p<0.0001). Patients treated with Dimebon were also significantly improved at six months over baseline on all measures (p=0.005 on ADAS-cog). Dimebon's benefit over placebo continued to increase throughout the 12-month treatment period. At the end of 12 months, Dimebon-treated patients preserved their starting level of function on each measure of Alzheimer's disease.

"In this study, Dimebon improved the clinical course of Alzheimer's disease, which is important given that the natural course is progressive deterioration over time," said Rachelle Doody, M.D., Ph.D., lead author and the Effie Marie Cain Chair in Alzheimer's Disease Research at
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
2. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
3. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
4. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
7. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
8. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
11. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Today the U.S. Food and Drug Administration ... prevention of serogroup B meningococcal disease in ... Trumenba®, which received FDA approval in October, represent a ... "I have heard over and over ...
(Date:1/23/2015)... 23, 2015 Research and Markets ( http://www.researchandmarkets.com/research/5dh22x/urinary_catheters ... Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and ... Size, Share, Growth, Trends and Forecast 2014 - 2020" ... At present, the global market for urinary catheters is ...
(Date:1/23/2015)... Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... DCVax® personalized immune therapies for operable and inoperable solid tumor ... present at the 7 th Annual Phacilitate Immunotherapy Forum ... Bio,s presentation at Phacilitate will take place on January 26 ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... Nov. 9, 2011 Reportlinker.com announces ... is available in its catalogue: ... in Europe - Reference Pricing and ... Drugs Pose Significant Challenge to Pharmaceutical ...
... Company (NYSE: KV.A/ KV.B) (the "Company" or "K-V"), today reported ... Food & Drug Administration ("FDA") approved product indicated to reduce ... who have a history of a singleton spontaneous preterm birth. ... 2011. From its launch date through October 31, 2011: ...
Cached Medicine Technology:Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 2Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 3Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 4Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 5Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 6Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 7K-V Pharmaceutical Announces Updated Makena® Performance Metrics 2K-V Pharmaceutical Announces Updated Makena® Performance Metrics 3K-V Pharmaceutical Announces Updated Makena® Performance Metrics 4K-V Pharmaceutical Announces Updated Makena® Performance Metrics 5K-V Pharmaceutical Announces Updated Makena® Performance Metrics 6K-V Pharmaceutical Announces Updated Makena® Performance Metrics 7K-V Pharmaceutical Announces Updated Makena® Performance Metrics 8
(Date:1/22/2015)... 22, 2015 Autocarinsurancebest.com has released a new ... commercial auto insurance policy . , Auto insurance quotes ... It is no longer necessary to call an agent or ... available online on a single website: http://autocarinsurancebest.com/ . , ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... January 22, 2015 JJsHouse.com is a famous ... Today, the business announces its latest collection of wedding ... “The most important issue is the wedding dress on your ... in a woman’s life. Every bride wants to find the ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... have discovered a key molecule needed to kill the blood ... institute,s Molecular Genetics of Cancer and Cancer and Haematology divisions ... to work the death- inducing molecule Bim is required. The ... on a two- or three-pronged attack on both the tumour ...
... researchers participated in more than 50 studies on improvements ... be presented at the 2011 Annual Meeting of the ... from June 3 through 7. Research highlights include: ... tumor response, adverse events and surgical complications in patients ...
... By Amanda Gardner HealthDay Reporter , SATURDAY, June ... common cancer drug, Avastin, may benefit both early stage ovarian ... In both studies, presented Saturday at the annual meeting of ... was added to standard chemotherapy. But the high ...
... the University of North Carolina at Chapel Hill School ... transplantation of adult stem cells enriched with a bone-regenerating ... not healing properly. The UNC study team led ... biomedical engineering, demonstrated that stem cells manufactured with the ...
... people with knee injuries could benefit from a new type ... The world,s first clinical trial for the treatment of patients ... regulatory agency, the MHRA1, to commence. The current ... the meniscus, a procedure that often results in the early ...
... indicates that longer time to beginning adjuvant chemotherapy after surgery ... a study in the June 8 issue of JAMA ... published early online to coincide with its presentation at the ... cancer (CRC) is the third leading cause of cancer mortality ...
Cached Medicine News:Health News:New strategy to attack tumor-feeding blood vessels 2Health News:City of Hope researchers to present rectal cancer, palliative care, benchmarking studies at ASCO 2Health News:City of Hope researchers to present rectal cancer, palliative care, benchmarking studies at ASCO 3Health News:Cancer Drug Avastin Makes Inroads Against Ovarian Tumors 2Health News:Cancer Drug Avastin Makes Inroads Against Ovarian Tumors 3Health News:Stem cell treatment may offer option for broken bones that don't heal 2Health News:Pioneering stem cell bandage receives approval for clinical trial 2Health News:Following colorectal cancer surgery, longer delay before chemotherapy associated with worse survival 2
... I system is a unique ... combines dual width capability with ... roll" design. Specifically developed to ... patients, the easy-to-use Tri-Flex I ...
... Max 10 Nebulizer W/ 7` CR Resistant ... for fast treatment times , ,Provide ... percentage of respirable particles) than conventional nebulizers, ... disposable nebulizers deliver fast and effective treatment ...
... 500ML 0.45% Sodium Chloride , ... ease of use. You can obtain heated and ... FIO 2 . We offer a wide selection ... sodium chloride inhalation, USP; and 0.9% sodium chloride ...
... Disposable Prefilled 28%-100% FIO 2 1000ML 0.45% ... ,Our prefilled nebulizers provide unmatched performance and ease ... high-output aerosols adjustable from 28% to 100% FIO ... solutions: sterile water for inhalation, USP; 0.45% sodium ...
Medicine Products: